PennyStocks101 Reports 3 TOP Stocks to Watch Closely: Oncolytics Biotech, Biolase Technology, and Mannkind Corp.

Beverly Hills, CA -- (SBWIRE) -- 02/08/2013 -- http://www.PennyStocks101.com - The US leader in microcap breakouts, offers a high quality stocks alert newsletter to investors looking for the best breakout stocks around. PennyStocks101 reports 3 penny stocks to keep an eye on for a possible bounce or more gains: ONCY, BIOL, and MNKD

A report on Friday revealing that the U.S. trade deficit narrowed in December helped push the market higher on Friday. The Dow Jones industrial average rose 49 points to 13,933 in mid day trading. It also briefly climbed back above 14,000 during morning trading. Standard & Poor's 500 index was up 7 points at 1,517 and the Nasdaq composite rose 29 points to 3,194.

1. Oncolytics Biotech (NASDAQ:ONCY) - Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers.

2. Biolase Technology (NASDAQ:BIOL) - Biolaw Technology, Inc. is the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine.

3. Mannkind Corp. (NASDAQ:MNKD) - Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases.

Pennystocks101.com educates and shows investors the inner workings of the volatile world of penny stocks by scouring the markets for the hottest penny stocks that look poised to break out. Discover the next hidden company to profit. Sign up for the free newsletter to receive the next big report soon. Join at: http://www.PennyStocks101.com

Sign Up at - http://www.PennyStocks101.com for more ideas to put on your radar.

Disclosure
Pennystocks101.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. This press release may contain several forward looking statements. Please read our report and visit our website for complete risks and disclosures.